Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study

By afschroeder • April 26, 2026

Berthelsen DB, Haugegaard T, Kamso MM, Tugwell P, Simon LS, Ioannidis JPA, Flurey C, Boers M, Voshaar M, Richards P, Shea B, Furst DE, Singh JA, Stevens R, Woodworth T, Bartlett SJ, Hazlewood GS, Christensen R; OMERACT Safety Working Group. Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study. Semin Arthritis Rheum. 2026 Apr 19;78:152983. doi: 10.1016/j.semarthrit.2026.152983. Epub ahead of print. PMID: 42034888.

Tags: Harms, OMERACT, Publications, Randomized Controlled Trials, Rheumatology, rheumatology, safety

Enhancing inpatient consultation workflow through implementation of an EHR direct-paging consult order system

Igawa T, Li-Fossum L, Zarrabi M, Kulkarni D, Lloyd J, Tseng B, Sim MS, McLitus M, Kozman DM, Ross MK. Enhancing inpatient consultation workflow through[...]

Characteristics and Outcomes of Over One Million Veterans with Heart Failure Phenotyped Using Artificial Intelligence Approaches: The National DCVA-HF Registry

Zhang S, Raman VK, Shao Y, Patel S, Cheng Y, Workman TE, Sheriff HM, Fonarow GC, Lam PH, Heidenreich PA, Morgan CJ, Moore HJ, Vargas[...]

Immune activation from M. tuberculosis screening tests predicts mortality

Seligman B, Ganz DA, Goetz MB, Beenhouwer DO. Immune activation from M. tuberculosis screening tests predicts mortality. Geroscience. 2026 Apr 27. doi: 10.1007/s11357-026-02221-y. Epub ahead[...]